NOP16 inhibitors are a class of chemical compounds that specifically target NOP16, a nucleolar protein involved in ribosome biogenesis and cell cycle regulation. NOP16 plays a key role in the early stages of ribosomal RNA (rRNA) processing and assembly, ensuring that the ribosomal subunits are correctly formed before being exported to the cytoplasm for protein synthesis. It is associated with the nucleolus, where ribosome production occurs, and is crucial for maintaining the balance of ribosome production relative to cellular growth needs. Inhibiting NOP16 can disrupt ribosomal biogenesis by preventing the correct assembly and maturation of ribosomal components, which affects the overall efficiency of protein synthesis within the cell.
The mechanism of action of NOP16 inhibitors typically involves binding to the protein's functional domains, preventing its interaction with other components of the ribosomal biogenesis machinery or blocking its role in rRNA processing. By inhibiting NOP16, these compounds hinder the formation of functional ribosomes, which can lead to downstream effects on cellular growth and division due to impaired protein synthesis. NOP16 inhibitors are valuable tools for studying the detailed mechanisms of ribosome production and how disruptions in this process impact cellular physiology. Researchers use these inhibitors to explore the intricacies of nucleolar function, ribosome assembly, and the role of NOP16 in regulating cell growth and proliferation, shedding light on the essential functions of ribosome biogenesis in maintaining cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide may decrease NOP16 expression by disrupting the binding of specific transcription factors essential for the initiation of the NOP16 gene transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D can bind to the NOP16 gene sequence and inhibit RNA polymerase, directly leading to reduced transcription of NOP16 mRNA. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Rocaglamide might specifically inhibit the initiation of translation for NOP16 mRNA, leading to a reduction in NOP16 protein production. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin can inhibit RNA polymerase II and consequently reduce the transcription rate of NOP16, resulting in lower NOP16 protein expression. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $99.00 | 5 | |
Cordycepin may prematurely terminate the elongation of NOP16 mRNA transcripts, which could result in decreased stability and abundance of NOP16 mRNA. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine can intercalate into NOP16 gene′s DNA, hindering the transcription process and leading to reduced synthesis of NOP16 mRNA. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 might bind to bromodomains near the NOP16 gene locus, preventing the recruitment of transcriptional machinery, thus decreasing NOP16 transcription. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin can inhibit the religation step of DNA topoisomerase I during transcription, causing DNA damage and halting the synthesis of NOP16 mRNA. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine (Decitabine) may downregulate NOP16 expression by inducing global changes in DNA methylation patterns, potentially leading to reduced transcriptional activity at the NOP16 gene promoter. | ||||||